Trial Details
COMPLETEDBasic Information
| Clinical ID | c1610 |
|---|---|
| Identifier | NCT04700449 |
| Trial Title | A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Moderate to Severe Ulcerative Colitis |
| Interventions | DRUG: Double-Blind 0.2mg CBP-307|DRUG: Double-Blind Placebo|DRUG: Open-label CBP-307|DRUG: Double-Blind 0.1mg CBP-307 |
Participant Information
| Sponsor | Connect Biopharm LLC |
|---|---|
| City | Phoenix |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2019-02-27 |
|---|---|
| Primary Completion Date | 2022-02-23 |
| Completion Date | 2022-11-10 |